APX-115

Research use only, not for human use.

APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.

APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively; shows no inhibitory activities on xanthine oxidase and glucose oxidase; inhibits the responses of BMMs to RANKL, including ROS generation, activation of MAPK and NF-κB, and osteoclast cells differentiation; protects db/db mice from renal injury.Diabetes Preclinical.

——

Animal Model:Six-week-old male diabetic db/db mice (C57BLKS/J-leprdb/leprdb)Dosage:60?mg/kg Administration:Oral gavage; per day; for 12 weeks Result:Significantly improved insulin resistance in diabetic mice.

Ewha 18278 | APX 115 | APX115

Membrane Transporter/Ion Channel

NADPH

NADPH

Metabolic Disease

Diabetes

1395946-75-4

315.801

C17H18ClN3O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (316.66 mM)

OC1=C(CCC)C(C2=CC=CC=C2)=NN1C3=NC=CC=C3.Cl

3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride

(-20℃)

With Ice Pack

≥ 2 years